Controversies in management of bacterial keratitis

International Ophthalmology Clinics

Volumn 45, Issue 4, 2005, Pages 199-210

  Charukamnoetkanok, Puwat ^a   Pineda II, Roberto ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CIPROFLOXACIN; CORTICOSTEROID; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; BACTERIUM CULTURE; CLINICAL PRACTICE; CORNEA ULCER; COST BENEFIT ANALYSIS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; KERATITIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

ANTI-BACTERIAL AGENTS; CORNEAL ULCER; DRUG RESISTANCE, BACTERIAL; EYE INFECTIONS, BACTERIAL; HUMANS; PRACTICE GUIDELINES;

EID: 27544504295     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iio.0000177432.66775.d2     Document Type: Review

References (54)

1. Gudmundsson OG, Ormerod LD, Kenyon KR, et al. Factors influencing predilection and outcome in bacterial keratitis. Cornea. 1989;8:115-121.
2. Whitcher JP. Corneal ulceration. Int Ophthalmol Clin. 1990;30:30-32.
3. Pepose JS, Wilhelmus KR. Divergent approaches to the management of corneal ulcers. Am J Ophthalmol 1992;114:630-632.
4. McDonnell PJ. Empirical or culture-guided therapy for microbial keratitis? A plea for data. Arch Ophthalmol. 1996;114:84-87.
5. Levey SB, Katz HR, Abrams DA, et al. The role of cultures in the management of ulcerative keratitis. Cornea. 1997;16:383-386.
6. Jones DB. Decision-making in the management of microbial keratitis. Ophthalmology. 1981;88:814-820.
7. McDonnell PJ, Nobe J, Gauderman WJ, et al. Community care of corneal ulcers. Am J Ophthalmol. 1992;114:531-538.
8. Baum JL, Initial therapy of suspected microbial corneal ulcers. I. Broad antibiotic therapy based on prevalence of organisms. Surv Ophthalmol. 1979;24:97-105.
9. Jones DB. Initial therapy of suspected microbial corneal ulcers. II. Specific antibiotic therapy based on corneal smears. Surv Ophthalmol. 1979;24:105-116.
10. Benson WH, Lanier JD. Comparison of techniques for culturing corneal ulcers. Ophthalmology. 1992;99:800-804.
11. Kowalski RP, Karenchak LM, Romanowski EG. Infectious disease: changing antibiotic susceptibility. Ophthalmol Clin North Am. 2003;16:1-9.
12. Wilhelmus KR, Schlech BA. Clinical and epidemiological advantages of culturing bacterial keratitis. Cornea. 2004;23:38-42.
13. Poggio EC, Glynn RJ, Schein OD, et al. The incidence of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. N Engl J Med. 1989;321:779-783.
14. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol. 1991;112:34S-47S.
15. Honig MA, Cohen EJ, Rapuano CJ, et al. Corneal ulcers and the use of topical fluoroquinolones. CLAO J. 1999;25:200-203.
16. O'Brien TP, Maguire MG, Fink NE, et al. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol 1995;113:1257-1265.
17. Hyndiuk RA, Eiferman RA, Caldwell DR, et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Ophthalmology. 1996;103: 1854-1862; discussion 1862-1863.
18. McLeod SD, Kolahdouz-Isfahani A, Rostamian K, et al. The role of smears, cultures, and antibiotic sensitivity testing in the management of suspected infectious keratitis. Ophthalmology. 1996;103:23-28.
19. Parks DJ, Abrams DA, Sarfarazi FA, et al. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis. Am J Ophthalmol. 1993;115:471-477.
20. The Ofloxacin Study Group. Ofloxacin monotherapy for the primary treatment of microbial keratitis: a double-masked, randomized, controlled trial with conventional dual therapy. Ophthalmology. 1997;104:1902-1909.
21. McLeod SD. Treatment of bacterial keratitis: an update. Comp Ophthalmol Update. 2001; 2:17-24.
22. McLeod SD, LaBree LD, Tayyanipour R, et al. The importance of initial management in the treatment of severe infectious corneal ulcers. Ophthalmology. 1995;102:1943-1948.
23. Chalupa E, Swarbrick HA, Holden BA, et al. Severe corneal infections associated with contact lens wear. Ophthalmology. 1987;94:17-22.
24. Schein OD, Glynn RJ, Poggio EC, et al. The relative risk of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. A case-control study. Microbial Keratitis Study Group. N Engl J Med. 1989;321:773-778.
25. Ormerod LD, Hertzmark E, Gomez DS, et al. Epidemiology of microbial keratitis in southern California. A multivariate analysis. Ophthalmology. 1987;94:1322-1333.
26. Rodman RC, Spisak S, Sugar A, et al. The utility of culturing corneal ulcers in a tertiary referral center versus a general ophthalmology clinic. Ophthalmology. 1997;104:1897-1901.
27. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology. 2000;107:1497-1502.
28. Kowal VO, Levey SB, Laibson PR, et al. Use of routine antibiotic sensitivity testing for the management of corneal ulcers. Arch Ophthalmol. 1997;115:462-465.
29. Ormerod LD, Heseltine PN, Alfonso E, et al. Gentamicin-resistant pseudomonal infection. Rationale for a redefinition of ophthalmic antimicrobial sensitivities. Cornea. 1989;8:195-199.
30. Asbell P, Stenson S. Ulcerative keratitis. Survey of 30 years' laboratory experience. Arch Ophthalmol. 1982;100:77-80.
31. Morlet N, Dart J. Routine antibiotic sensitivity testing for corneal ulcers. Arch Ophthalmol. 1998;116:1262-1263.
32. McLeod SD. The role of cultures in the management of ulcerative keratitis. Cornea. 1997;16:381-382.
33. Pineda R II, Dohlman CH. Adjunctive therapy and surgical considerations in the management of bacterial ulcerative keratitis. Int Ophthalmol Clin. 1996;36:37-48.
34. Kowalski RP, Pandya AN, Karenchak LM, et al. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa. Ophthalmology. 2001;108:1826-1829.
35. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratins: a 5-year review. Ophthalmology. 1999;106:1313-1318.
36. Knauf HP, Silvany R, Southern PM Jr, et al. Susceptibility of corneal and conjunctival pathogens to ciprofloxacin. Cornea. 1996;15:66-71.
37. Schmidt FR. The challenge of multidrug resistance: actual strategies in the development of novel antibacterials. Appl Microbiol Biotechnol. 2004;63:335-343.
38. Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N Engl J Med. 1996;335: 1445-1453.
39. Hodge WG, Bui DP, Cevallos V, et al. Frequency of recovery of ciprofloxacin-resistant ocular isolates following topical ciprofloxacin therapy. Invest Ophthalmol Vis Sci. 1995;36: S155.
40. Drake JD, Bui D, Hwang DG. Mutagenic effects of subinhibitory levels of ciprofloxacin and their relationship to antibiotic resistance. Invest Ophthalmol Vis Sci. 1997;38: S871.
41. Mather R, Karenchak LM, Romanowski EG, et al. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463-466.
42. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 2003;136:500-505.
43. Aronson SB, Moore TEJ. Corticosteroid therapy of central stromal keratitis. Am J Ophthalmol. 1969;67:873-896.
44. Leibowitz HM. Management of inflammation in the cornea and conjunctiva. Ophthalmology. 1980;87:753-758.
45. Leibowitz HM, Kupferman A. Topically administered corticosteroids: effect on antibiotic-treated bacterial keratitis. Arch Ophthalmol. 1980;98:1287-1290.
46. Stern GA, Buttross M. Use of corticosteroids in combination with antimicrobial drugs in the treatment of infectious corneal disease. Ophthalmology. 1991;98:847-853.
47. Wilhelmus KR. Indecision about corticosteroids for bacterial keratitis: an evidence-based update. Ophthalmology. 2002;109:835-842; quiz 843.
48. O'Day DM. Corticosteroids: an unresolved debate. Ophthalmology. 1991;98:845-846.
49. Carmichael TR, Gelfand Y, Welsh NH. Topical steroids in the treatment of central and paracentral corneal ulcers. Br J Ophthalmol. 1990;74:528-531.
50. Davis SD, Sarff LD, Hyndiuk RA. Corticosteroid in experimentally induced Pseudomonas keratitis: failure of prednisolone to impair the efficacy of tobramycin and carbenicillin therapy. Arch Ophthalmol. 1978;96:126-128.
51. Smolin G, Okumoto M, Leong-Sit L. Combined gentamicin-tobramycin- corticosteroid treatment. II. Effect on gentamicin-resistant Pseudomonas keratitis. Arch Ophthalmol. 1980;98:473-474.
52. Badenoch PR, Hay GJ, McDonald PJ, et al. A rat model of bacterial keratitis. Effect of antibiotics and corticosteroid. Arch Ophthalmol. 1985;103:718-722.
53. Burns PR. Pseudomonas aeruginosa keratitis: mixed infections of the eye. Am J Ophthalmol. 1969;67:257-262.
54. Harbin T. Recurrence of a corneal Pseudomonas infection after topical steroid therapy: report of a case. Am J Ophthalmol 1964;58:670-674.